A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma

StatusRecruiting
PhasePhase 1/2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial sites expanded: 6 → 9 locations
    • Interventions: TORL-5-700 (Drug), TORL-5-700 at MTD/RP2D (Drug), TORL-5-700 at MTD/RP2D in combination with another agent (Drug) to TORL-5-700 (Drug), TORL-5-700 at MTD/RP2D (Drug), TORL-5-700 at MTD/RP2D in combination with another agent (Drug)
    • Eligibility criteria expanded, about 12 words
    • Secondary endpoints: details revised at 2 of 13 entries
  2. Trial sites expanded: 3 → 6 locationsv3
  3. Recruitment opened
    • Trial sites expanded: 0 → 3 locations
    • Start date changed from estimate of Jan 30, 2026 to Mar 31, 2026
    v2
  4. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A Phase 1/2 study to evaluate safety, tolerability, and anticancer activity of TORL-5-700 as a monotherapy and in combination in R/R NHL
Trial Details
NCT Number NCT07439653
Lead Sponsor TORL Biotherapeutics, LLC
Conditions
(from sponsor)		 Histologically Confirmed Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Related terms Lymphoma, B-Cell
Enrollment 155 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov